Novartis' INVEST-HD Phase 3 trial: Site Initiations in USA and Canada
Community Update:
Novartis’ INVEST-HD Phase 3 trial: Site
Initiations in USA and Canada
March 16th, 2026
Dear Huntington’s Disease Community,
We are delighted to share an update on the development of votoplam (formerly PTC518).
Last month we shared the news that the votoplam Phase 3 clinical trial, INVEST-HD, has been posted on ClinicalTrials.gov. Further progress to initiate the study has been made since then:
• We have activated our first sites for the study. This means that the study is now open for participant
enrollment at these hospitals/centers.
• To date, we have activated two sites in North America (one each in USA and Canada) and more sites
will follow in these countries as well as in well as in more countries.
• The study aims to recruit about 770 study participants from over 30 countries worldwide.
• The list of participating study sites will be updated regularly on ClinicalTrials.gov over the coming weeks and months, as sites come on board.
About the INVEST-HD study
INVEST-HD is a global pivotal Phase 3 clinical trial designed to evaluate the safety and efficacy of votoplam, an investigational oral medicine for Huntington’s disease. The aim of the study is to see whether votoplam can slow the progression of Huntington’s disease in people in the early stages of the condition.
The study builds on findings from earlier research, including the Phase 2 PIVOT-HD study. While current treatments can help manage symptoms of HD, there remains a high unmet need for therapies that could slow the progression of the disease. As with all clinical studies, participant safety is a top priority, and their health will be carefully monitored throughout the duration of this study.
You can view the INVEST-HD study (NCT7326709) information here: Study Details | NCT07326709 | A Study to Investigate the Efficacy, Safety and Tolerability of Votoplam in Participants With Huntington's Disease | ClinicalTrials.gov. Please note that updating the information on this platform may take some time.
Novartis remains committed to transparency, collaboration with the HD community, and sharing updates as the development continues. We encourage anyone who is interested to review the study information posted on ClinicalTrials.gov and to speak to their healthcare provider.
Kind regards,
Votoplam Clinical Development Team at Novartis
I like the quick gameplay in Drift Boss. There is no need to spend a long time learning complicated rules. Just focus on the corners, improve your timing, and see how far you can get.
A family friend has spent years supporting a relative living with a progressive neurological condition, so I have seen how important research updates can be for families facing uncertainty. Progress toward new treatment options can bring hope, although clinical trials need careful monitoring and reliable evidence before results are known. Clear communication also helps people understand study eligibility and discuss questions with their healthcare providers. Students researching medical developments may need extra time to understand complex information, and Assignment Help Nottingham can support them with demanding academic tasks.
Exciting progress from Novartis! The INVEST-HD Phase 3 trial moving forward with site initiations in the USA and Canada marks a significant step in advancing potential treatments for Huntington’s disease. Looking forward to the results and the impact this could have on patients and families affected by this condition. Gulf Book Publishers.
Me interesa. Somos pacientes Huntington familiares